H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015

Published: Dec, 2015 | Pages: 219 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015', provides an overview of the H5N1 Infection (Avian Influenza)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
H5N1 Infection (Avian Influenza) Overview 10
Therapeutics Development 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 11
Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 12
H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 13
H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 18
H5N1 Infection (Avian Influenza) - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
H5N1 Infection (Avian Influenza) - Products under Development by Companies 22
H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 27
H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 28
Akshaya Bio Inc. 28
Altimmune, Inc. 29
Antigen Express, Inc. 30
Aphios Corporation 31
Aprogen, Inc. 32
BioDiem Ltd 33
BiondVax Pharmaceuticals Ltd. 34
CEL-SCI Corporation 35
Cocrystal Pharma, Inc. 36
CSL Limited 37
Daiichi Sankyo Company, Limited 38
Emergent BioSolutions Inc. 39
Gemmus Pharma Inc. 40
GlaxoSmithKline Plc 41
Green Cross Corporation 42
Hemispherx Biopharma, Inc. 43
iBio, Inc. 44
Immunovaccine, Inc. 45
Inovio Pharmaceuticals, Inc. 46
Johnson & Johnson 47
Kineta, Inc. 48
Medicago Inc. 49
MedImmune, LLC 50
Microbiotix, Inc. 51
Microgen Scientific Industrial Company for Immunobiological Medicines 52
Myelo Therapeutics GmbH 53
NanoBio Corporation 54
Nanotherapeutics, Inc. 55
NanoViricides, Inc. 56
NewLink Genetics Corporation 57
OPKO Health, Inc. 58
PaxVax, Inc. 59
PDS Biotechnology Corporation 60
PeptiDream Inc. 61
Protein Sciences Corporation 62
Shionogi & Co., Ltd. 63
Sirnaomics, Inc. 64
Takeda Pharmaceutical Company Limited 65
TechnoVax, Inc. 66
Theraclone Sciences, Inc. 67
Vaxine Pty Ltd 68
VaxInnate Corporation 69
H5N1 Infection (Avian Influenza) - Therapeutics Assessment 70
Assessment by Monotherapy Products 70
Assessment by Combination Products 71
Assessment by Target 72
Assessment by Mechanism of Action 74
Assessment by Route of Administration 76
Assessment by Molecule Type 78
Drug Profiles 80
A-06 - Drug Profile 80
AE-443p - Drug Profile 81
Alferon LDO - Drug Profile 83
AP-302 - Drug Profile 84
APP-0205 - Drug Profile 85
APP-309 - Drug Profile 86
AT-301 - Drug Profile 87
CEL-1000 - Drug Profile 88
DP-C005 - Drug Profile 90
FBF-001 - Drug Profile 91
FDX-000 - Drug Profile 92
Gamma-Flu - Drug Profile 93
GP-1001 - Drug Profile 94
GP-1002 - Drug Profile 95
GP-1681 - Drug Profile 96
GREFLU/VIE - Drug Profile 98
HAI-05 - Drug Profile 99
iHA-24 - Drug Profile 100
Influ-nRNA - Drug Profile 101
influenza (strain H5N1, H1N1) vaccine - Drug Profile 102
influenza [strain A/H5N1] vaccine - Drug Profile 103
influenza [strain A/H5N1] vaccine - Drug Profile 104
influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile 105
influenza [strain H5N1] (split virion) vaccine - Drug Profile 106
influenza [strain H5N1] vaccine - Drug Profile 107
influenza [strain H5N1] vaccine - Drug Profile 108
influenza [strain H5N1] vaccine - Drug Profile 109
influenza [strain H5N1] vaccine - Drug Profile 110
influenza [strain H5N1] vaccine - Drug Profile 112
influenza [strain H5N1] vaccine - Drug Profile 113
influenza [strain H5N1] vaccine - Drug Profile 114
influenza [strain H5N1] vaccine - Drug Profile 115
influenza [strain H5N1] vaccine - Drug Profile 116
influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 117
influenza [strain H5N1] virus like particles vaccine - Drug Profile 119
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 121
influenza A vaccine - Drug Profile 122
influenza vaccine - Drug Profile 123
influenza vaccine - Drug Profile 124
influenza virus like particle vaccine - Drug Profile 126
Innate Immune Adjuvants - Drug Profile 127
INO-3510 - Drug Profile 128
IPS-07 series - Drug Profile 129
JNJ-872 - Drug Profile 130
KD-295 - Drug Profile 132
KIB-PCI - Drug Profile 133
M-001 - Drug Profile 134
MBX-2329 - Drug Profile 137
MBX-2546 - Drug Profile 139
MEDI-550 - Drug Profile 140
MG-1109 - Drug Profile 142
Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile 144
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 145
MVAH-5HA - Drug Profile 146
Myelo-001 - Drug Profile 147
NVINF-1 - Drug Profile 148
NVINF-2 - Drug Profile 150
OrniFlu - Drug Profile 151
PanBlok - Drug Profile 152
PDS-0102 - Drug Profile 154
PNSIA-28 - Drug Profile 155
PNSIA-49 - Drug Profile 156
PXVX-0103 - Drug Profile 157
rintatolimod - Drug Profile 159
S-033188 - Drug Profile 161
Small Molecules to Activate Sirtuin for Influenza - Drug Profile 162
Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 163
STP-702 - Drug Profile 164
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 165
TCN-032 - Drug Profile 166
TVX-003 - Drug Profile 168
VAX-161 - Drug Profile 169
VGX-3400X - Drug Profile 170
VH-244 - Drug Profile 172
H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 174
H5N1 Infection (Avian Influenza) - Dormant Projects 200
H5N1 Infection (Avian Influenza) - Discontinued Products 205
H5N1 Infection (Avian Influenza) - Product Development Milestones 206
Featured News & Press Releases 206
Appendix 213
Methodology 213
Coverage 213
Secondary Research 213
Primary Research 213
Expert Panel Validation 213
Contact Us 213
Disclaimer 214

List of Tables

Number of Products under Development for H5N1 Infection (Avian Influenza), H2 2015 16
Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H2 2015 17
Number of Products under Development by Companies, H2 2015 19
Number of Products under Development by Companies, H2 2015 (Contd..1) 20
Number of Products under Development by Companies, H2 2015 (Contd..2) 21
Number of Products under Development by Companies, H2 2015 (Contd..3) 22
Number of Products under Investigation by Universities/Institutes, H2 2015 23
Comparative Analysis by Late Stage Development, H2 2015 24
Comparative Analysis by Clinical Stage Development, H2 2015 25
Comparative Analysis by Early Stage Development, H2 2015 26
Products under Development by Companies, H2 2015 27
Products under Development by Companies, H2 2015 (Contd..1) 28
Products under Development by Companies, H2 2015 (Contd..2) 29
Products under Development by Companies, H2 2015 (Contd..3) 30
Products under Development by Companies, H2 2015 (Contd..4) 31
Products under Investigation by Universities/Institutes, H2 2015 32
H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H2 2015 33
H5N1 Infection (Avian Influenza) - Pipeline by Altimmune, Inc., H2 2015 34
H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H2 2015 35
H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H2 2015 36
H5N1 Infection (Avian Influenza) - Pipeline by Aprogen, Inc., H2 2015 37
H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H2 2015 38
H5N1 Infection (Avian Influenza) - Pipeline by BiondVax Pharmaceuticals Ltd., H2 2015 39
H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H2 2015 40
H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H2 2015 41
H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H2 2015 42
H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 43
H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H2 2015 44
H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H2 2015 45
H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H2 2015 46
H5N1 Infection (Avian Influenza) - Pipeline by Green Cross Corporation, H2 2015 47
H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H2 2015 48
H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H2 2015 49
H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H2 2015 50
H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H2 2015 51
H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H2 2015 52
H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H2 2015 53
H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H2 2015 54
H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H2 2015 55
H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H2 2015 56
H5N1 Infection (Avian Influenza) - Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H2 2015 57
H5N1 Infection (Avian Influenza) - Pipeline by Myelo Therapeutics GmbH, H2 2015 58
H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H2 2015 59
H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H2 2015 60
H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H2 2015 61
H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H2 2015 62
H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H2 2015 63
H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H2 2015 64
H5N1 Infection (Avian Influenza) - Pipeline by PDS Biotechnology Corporation, H2 2015 65
H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H2 2015 66
H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H2 2015 67
H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H2 2015 68
H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H2 2015 69
H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 70
H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H2 2015 71
H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H2 2015 72
H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H2 2015 73
H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H2 2015 74
Assessment by Monotherapy Products, H2 2015 75
Assessment by Combination Products, H2 2015 76
Number of Products by Stage and Target, H2 2015 78
Number of Products by Stage and Mechanism of Action, H2 2015 80
Number of Products by Stage and Route of Administration, H2 2015 82
Number of Products by Stage and Molecule Type, H2 2015 84
H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H2 2015 179
H5N1 Infection (Avian Influenza) - Dormant Projects, H2 2015 205
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H2 2015 206
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H2 2015 207
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H2 2015 208
H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H2 2015 209
H5N1 Infection (Avian Influenza) - Discontinued Products, H2 2015 210